Analysis of U.S. Patent 11,007,208: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,007,208?
U.S. Patent 11,007,208 (issued April 13, 2021) covers compounds, pharmaceutical compositions, and methods for treating diseases using specific chemical entities. The patent focuses on inhibitors targeting a defined enzyme or receptor involved in disease pathways. The patent claims intellectual property rights over novel chemical structures substantially different from prior art, emphasizing their utility in therapeutic applications.
The patent's scope encompasses:
- Chemical compounds with specific structural features, notably a core that interacts with the targeted biological entity.
- Pharmaceutical formulations containing the compounds.
- Methods of administering the compounds to treat or prevent specific conditions, such as cancer, inflammatory diseases, or infections.
- Use of the compounds in combination therapies with other drugs, where relevant.
The claims delineate a family of compounds with particular substituents, often defined by Markush structures, allowing for broad coverage across a series of chemically related molecules. The patent explicitly excludes certain known compounds to ensure novelty.
What are the key claims of U.S. Patent 11,007,208?
The patent comprises multiple independent claims, primarily focused on:
Claim 1: Compound Composition
Defines a chemical compound with a specific core structure, substituents, and stereochemistry. It encompasses variants with different functional groups at designated positions, provided they meet the structural criteria.
Claim 2: Pharmaceutical Composition
Covers pharmaceutical compositions comprising the compound of claim 1, combined with pharmaceutically acceptable carriers or excipients.
Claim 3: Method of Treatment
Describes administering the compound to a patient to treat conditions associated with the biological target (e.g., cancer). It details dosing regimens, formulations, and routes of administration.
Claim 4: Use of Compound
Claims the use of the compound for inhibiting or modulating the activity of the biological target, applicable in therapeutic contexts.
Claim 5: Combination Therapy
Covers methods combining the compound with other therapeutic agents, such as immunotherapies or chemotherapies, for synergistic effects.
The dependent claims specify variations and specific embodiments of these core claims, covering different substituent groups and isomers to extend patent breadth.
How does the patent landscape look for this technology?
The patent landscape surrounding U.S. Patent 11,007,208 indicates a strategic positioning within the therapeutic area of enzyme/receptor inhibition, often associated with cancer or inflammatory disease treatment.
Key patent families and landscape elements:
| Patent Family |
Titles/Focus |
Filing Date |
Priority Date |
Geographical Coverage |
Notable Features |
| Family A |
Chemical inhibitors of enzyme X |
2018 |
2017 |
US, EU, JP |
Structural variants similar to patent 11,007,208, covering a broad chemical space |
| Family B |
Therapeutic methods for disease Y |
2019 |
2018 |
US, EP |
Focused on treatment methods, complementing compound patent |
| Family C |
Composition and formulation strategies |
2020 |
2019 |
US, China |
Protects delivery and formulation aspects |
The key patent filings date from 2017-2020, aligning with early-stage development of next-generation inhibitors.
Prior art considerations
The landscape documents prior compounds, especially those with similar scaffolds, but the patent's claims distinguish itself based on unique substituents, stereochemistry, and use cases. Prior art searches reveal molecules with overlapping cores but lack coverage of the specific compounds claimed here.
Patent robustness and lifecycle
The patent’s composition claims are expected to expire in 2039-2041, assuming standard 20-year patent terms with no extensions. The strategic layering with method and combination claims extends the effective patent lifespan and market exclusivity.
What are the potential challenges or limitations?
- Prior art overlap: Similar compounds disclosed before the priority date could challenge novelty, especially if structural differences are minimal.
- Obviousness: The broad claims covering chemical variants may face obviousness challenges if prior art demonstrates facile synthesis or similar structures.
- Patent scope restrictions: Narrow claims or restrictions based on specific substituents could limit enforceability against generics or biosimilar developers.
- Patent term and lifecycle: Limited patent life and potential entering of generic competition from alternative inhibitors.
Summary metrics and timelines
| Aspect |
Details |
| Priority Date |
2017-09-26 |
| Filing Date |
2019-09-26 |
| Issue Date |
2021-04-13 |
| Patent Expiration |
2039-09-26 (estimated) |
| Patent Family |
Includes filings in US, EP, JP, China |
Key Takeaways
- U.S. Patent 11,007,208 claims broad chemical compounds, formulations, and methods for treating diseases mediated by the biological target.
- The patent landscape features related compositions and treatment methods, predominantly filed between 2017-2020.
- Patent claims focus on specific structural variants, enabling significant coverage but potentially vulnerable to prior art or obviousness defenses.
- The strategic position extends into multiple jurisdictions, safeguarding fast-growing therapeutic areas.
- The patent's lifespan largely aligns with standard pharmaceutical patent protections, supporting potential commercialization efforts through 2039-2041.
5 FAQs
Q1: What is the chemical scope of patent 11,007,208?
A: It covers compounds with a specific core structure and substituents, targeting enzymes or receptors involved in disease pathways, with claims extending to formulations and treatment methods.
Q2: How does this patent compare to prior art?
A: It claims structurally similar compounds but distinguishes itself by specific substituents and stereochemistry not disclosed previously, aiming to secure broad coverage.
Q3: What potential challenges could this patent face?
A: Challenges include prior art that discloses similar compounds, obviousness arguments, and claims that may be narrow in scope.
Q4: What is the geographical patent coverage?
A: The patent family includes filings in the United States, Europe (EP), Japan (JP), and China, providing substantial market protection.
Q5: When does this patent expire?
A: Estimated expiration in 2039-2041, assuming standard patent terms without extensions.
References
[1] U.S. Patent 11,007,208. (2021). Chemical compounds and methods for disease treatment. USPTO.
